Idorsia Ltd (IDIA.SW)
CHF 1.3
(2.45%)
CHF 1.3
(2.45%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -297.92 Million CHF | 64.01% |
| 2022 | -827.89 Million CHF | -30.46% |
| 2021 | -634.59 Million CHF | -42.57% |
| 2020 | -445.11 Million CHF | 10.01% |
| 2019 | -494.64 Million CHF | -28.02% |
| 2018 | -386.39 Million CHF | -2607.9% |
| 2017 | -14.26 Million CHF | 95.74% |
| 2016 | -335.14 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -101 Million CHF | 6.98% |
| 2024 Q1 | 29.86 Million CHF | 125.59% |
| 2024 Q2 | -108.57 Million CHF | -463.61% |
| 2023 Q3 | 224.04 Million CHF | 216.02% |
| 2023 FY | -297.92 Million CHF | 64.01% |
| 2023 Q1 | -212.18 Million CHF | -10.05% |
| 2023 Q2 | -193.11 Million CHF | 8.99% |
| 2023 Q4 | -116.67 Million CHF | -152.08% |
| 2022 Q3 | -215.95 Million CHF | 2.54% |
| 2022 FY | -827.89 Million CHF | -30.46% |
| 2022 Q4 | -192.81 Million CHF | 10.71% |
| 2022 Q2 | -221.57 Million CHF | -12.16% |
| 2022 Q1 | -197.55 Million CHF | 21.49% |
| 2021 FY | -634.59 Million CHF | -42.57% |
| 2021 Q4 | -251.64 Million CHF | -80.28% |
| 2021 Q3 | -139.58 Million CHF | -0.54% |
| 2021 Q2 | -138.83 Million CHF | -32.82% |
| 2021 Q1 | -104.53 Million CHF | 23.68% |
| 2020 FY | -445.11 Million CHF | 10.01% |
| 2020 Q3 | -118.48 Million CHF | -70.93% |
| 2020 Q1 | -120.03 Million CHF | 15.33% |
| 2020 Q2 | -69.31 Million CHF | 42.25% |
| 2020 Q4 | -136.96 Million CHF | -15.6% |
| 2019 Q2 | -125.55 Million CHF | -18.0% |
| 2019 Q1 | -106.4 Million CHF | 1.69% |
| 2019 FY | -494.64 Million CHF | -28.02% |
| 2019 Q4 | -141.76 Million CHF | -18.24% |
| 2019 Q3 | -119.88 Million CHF | 4.51% |
| 2018 Q3 | -119.12 Million CHF | -48.1% |
| 2018 Q1 | -78.6 Million CHF | -221.0% |
| 2018 FY | -386.39 Million CHF | -2607.9% |
| 2018 Q4 | -108.23 Million CHF | 9.14% |
| 2018 Q2 | -80.43 Million CHF | -2.32% |
| 2017 FY | -14.26 Million CHF | 95.74% |
| 2017 Q1 | -114.67 Million CHF | 0.0% |
| 2017 Q2 | 103.39 Million CHF | 190.16% |
| 2017 Q4 | 64.96 Million CHF | 191.75% |
| 2017 Q3 | -70.8 Million CHF | -168.48% |
| 2016 FY | -335.14 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.55 Million CHF | -2722.23% |
| BB Biotech AG | -206.6 Million CHF | -44.197% |
| Basilea Pharmaceutica AG | 10.45 Million CHF | 2950.646% |
| Evolva Holding SA | -105.22 Million CHF | -183.116% |
| Kuros Biosciences AG | -13.72 Million CHF | -2070.329% |
| Molecular Partners AG | -61.98 Million CHF | -380.642% |
| Relief Therapeutics Holding AG | -98.18 Million CHF | -203.441% |
| Santhera Pharmaceuticals Holding AG | 54.78 Million CHF | 643.83% |